alexa Understanding The Epigenetic Response In Resistant Cancer Cells To Romidepsin Therapy
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Ellen McAuley
University of Liverpool, UK
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-023
Abstract
The histone deacetylase inhibitor (HDACi) romidepsin has shown therapeutic potential in the treatment of peripheral and cutaneous T cell lymphoma although resistance to this novel therapeutic agent often develops. Multiple mechanisms of resistance to HDACis have been identified in vitro, but how this class of epigenetic inhibitors manipulates the epigenome and whether this is altered to cause development of tolerance in cancer cells has not been studied. Previous work in the department into HDACi resistance has identified candidate epigenetic genes, including HDAC8 and KDM5A, whose mRNA expression pattern is perturbed in response to HDACi treatment in multiple romidepsin resistant cell lines. However, whether these alterations in mRNA levels reflect protein expression and functional changes remains unclear. Using the CTCL cell line HuT78 and its romidepsin resistant counterpart (RHuT78), it was shown that both HDAC8 and the KDM5A protein expression are altered differently between the wild type and the resistant cell line upon treatment with romidepsin. Furthermore, by combining romidepsin treatment with the DNA methyltransferase inhibitor 5-azacytidine and inducing an apoptotic response in RHuT78 cells, the expression changes of HDAC8 and KDM5A could be transformed back to that seen in the parental HuT78 cell line. These results suggest that both HDAC8 and KDM5A may contribute towards defining resistant responses to HDACis and are therefore worthy for further study into potential therapeutic targets for inhibition to overcome resistance to romidepsin.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords